This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Welsh, S. J. Articles by Powis, G. Search for Related Content PubMed PubMed Citation Articles by Welsh, S. J. Articles by Powis, G.

The Redox Protein Thioredoxin-1 (Trx-1) Increases Hypoxia-inducible Factor 1 Protein Expression

Trx-1 Overexpression Results in Increased Vascular Endothelial Growth Factor Production and Enhanced Tumor Angiogenesis¹

Arizona Cancer Center [S. J. W., G. P.] and Department of Pathology [W. T. B., M. M. B.], University of Arizona, Tucson, Arizona, 85724-5024

Hypoxia-inducible factor 1 (HIF-1), a heterodimer of HIF-1 and HIF-1ß subunits, is a transcriptional activator central to the cellular response to low oxygen that includes metabolic adaptation, angiogenesis, metastasis, and inhibited apoptosis. Thioredoxin-1 (Trx-1) is a small redox protein overexpressed in a number of human primary tumors. We have examined the effects of Trx-1 on HIF activity and the activation of downstream genes. Stable transfection of human breast carcinoma MCF-7 cells with human Trx-1 caused a significant increase in HIF-1 protein levels under both normoxic (20% oxygen) and hypoxic (1% oxygen) conditions. Trx-1 increased hypoxia-induced HIF-1 transactivation activity measured using a luciferase reporter under the control of the hypoxia response element. Changes in HIF-1 mRNA levels did not account for the changes observed at the protein level, and HIF-1ß protein levels did not change. Trx-1 transfection also caused a significant increase in the protein products of hypoxia-responsive genes, including vascular endothelial growth factor (VEGF) and nitric oxide synthase 2 in a number of different cell lines (MCF-7 human breast and HT29 human colon carcinomas and WEHI7.2 mouse lymphoma cells) under both normoxic and hypoxic conditions. The pattern of expression of the different isoforms of VEGF was not changed by Trx-1. Transfection of a redox-inactive Trx-1 (C32S/C35S) markedly decreased levels of HIF-1 protein, HIF-1 transactivating activity, and VEGF protein in MCF-7 cells compared with empty vector controls. In vivo studies using WEHI7.2 cells transfected with Trx-1 showed significantly increased tumor VEGF and angiogenesis. The results suggest that Trx-1 increases HIF-1 protein levels in cancer cells and increases VEGF production and tumor angiogenesis.

This article has been cited by other articles:

				S. Yan, C. Zhou, X. Lou, Z. Xiao, H. Zhu, Q. Wang, Y. Wang, N. Lu, S. He, Q. Zhan, et al. PTTG Overexpression Promotes Lymph Node Metastasis in Human Esophageal Squamous Cell Carcinoma Cancer Res., April 15, 2009; 69(8): 3283 - 3290. [Abstract] [Full Text] [PDF]

				S. R. Thom Oxidative stress is fundamental to hyperbaric oxygen therapy J Appl Physiol, March 1, 2009; 106(3): 988 - 995. [Abstract] [Full Text] [PDF]

				T. N. Milovanova, V. M. Bhopale, E. M. Sorokina, J. S. Moore, T. K. Hunt, M. Hauer-Jensen, O. C. Velazquez, and S. R. Thom Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo J Appl Physiol, February 1, 2009; 106(2): 711 - 728. [Abstract] [Full Text] [PDF]

				T. N. Milovanova, V. M. Bhopale, E. M. Sorokina, J. S. Moore, T. K. Hunt, M. Hauer-Jensen, O. C. Velazquez, and S. R. Thom Lactate Stimulates Vasculogenic Stem Cells via the Thioredoxin System and Engages an Autocrine Activation Loop Involving Hypoxia-Inducible Factor 1 Mol. Cell. Biol., October 15, 2008; 28(20): 6248 - 6261. [Abstract] [Full Text] [PDF]

				A Mukherjee and S G Martin The thioredoxin system: a key target in tumour and endothelial cells Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S57 - S68. [Abstract] [Full Text] [PDF]

				A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF]

				J. Zhou, A. E. Damdimopoulos, G. Spyrou, and B. Brune Thioredoxin 1 and Thioredoxin 2 Have Opposed Regulatory Functions on Hypoxia-inducible Factor-1{alpha} J. Biol. Chem., March 9, 2007; 282(10): 7482 - 7490. [Abstract] [Full Text] [PDF]

				C. Berndt, C. H. Lillig, and A. Holmgren Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1227 - H1236. [Abstract] [Full Text] [PDF]

				M. K.C. Ng, J. Wu, E. Chang, B.-y. Wang, R. Katzenberg-Clark, A. Ishii-Watabe, and J. P. Cooke A Central Role for Nicotinic Cholinergic Regulation of Growth Factor-Induced Endothelial Cell Migration Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 106 - 112. [Abstract] [Full Text] [PDF]

				S. Patiar and A. L Harris Role of hypoxia-inducible factor-1{alpha} as a cancer therapy target Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S61 - S75. [Abstract] [Full Text] [PDF]

				D. T. Jones, C. W. Pugh, S. Wigfield, M. F.G. Stevens, and A. L. Harris Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-{alpha} Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation. Clin. Cancer Res., September 15, 2006; 12(18): 5384 - 5394. [Abstract] [Full Text] [PDF]

				D. G. Peters, W. Ning, T. J. Chu, C. J. Li, and A. M. K. Choi Comparative SAGE analysis of the response to hypoxia in human pulmonary and aortic endothelial cells Physiol Genomics, September 14, 2006; 26(2): 99 - 108. [Abstract] [Full Text] [PDF]

				D. T. Jones and A. L. Harris Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol. Cancer Ther., September 1, 2006; 5(9): 2193 - 2202. [Abstract] [Full Text] [PDF]

				R. Yang, D. J. Weber, and F. Carrier Post-transcriptional regulation of thioredoxin by the stress inducible heterogenous ribonucleoprotein A18 Nucleic Acids Res., March 2, 2006; 34(4): 1224 - 1236. [Abstract] [Full Text] [PDF]

				G. Powis, P. Wipf, S. M. Lynch, A. Birmingham, and D. L. Kirkpatrick Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol. Cancer Ther., March 1, 2006; 5(3): 630 - 636. [Abstract] [Full Text] [PDF]

				I. Csiki, K. Yanagisawa, N. Haruki, S. Nadaf, J. D. Morrow, D. H. Johnson, and D. P. Carbone Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1{alpha} in Non-Small Cell Lung Cancer Cancer Res., January 1, 2006; 66(1): 143 - 150. [Abstract] [Full Text] [PDF]

				N.-M. Chau, P. Rogers, W. Aherne, V. Carroll, I. Collins, E. McDonald, P. Workman, and M. Ashcroft Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1{alpha} Induction in Response to Hypoxic Stress and Growth Factors Cancer Res., June 1, 2005; 65(11): 4918 - 4928. [Abstract] [Full Text] [PDF]

				B. F. Jordan, M. Runquist, N. Raghunand, R. J. Gillies, W. R. Tate, G. Powis, and A. F. Baker The Thioredoxin-1 Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced Magnetic Resonance Imaging Clin. Cancer Res., January 15, 2005; 11(2): 529 - 536. [Abstract] [Full Text] [PDF]

				K. D. Mansfield, M. C. Simon, and B. Keith Hypoxic reduction in cellular glutathione levels requires mitochondrial reactive oxygen species J Appl Physiol, October 1, 2004; 97(4): 1358 - 1366. [Abstract] [Full Text] [PDF]

				D. Mustacich, A. Wagner, R. Williams, W. Bair, L. Barbercheck, S. P. Stratton, A. K. Bhattacharyya, and G. Powis Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse Carcinogenesis, October 1, 2004; 25(10): 1983 - 1989. [Abstract] [Full Text] [PDF]

				T. Acker and H. Acker Cellular oxygen sensing need in CNS function: physiological and pathological implications J. Exp. Biol., August 15, 2004; 207(18): 3171 - 3188. [Abstract] [Full Text] [PDF]

				N. Wakisaka, S. Kondo, T. Yoshizaki, S. Murono, M. Furukawa, and J. S. Pagano Epstein-Barr Virus Latent Membrane Protein 1 Induces Synthesis of Hypoxia-Inducible Factor 1{alpha} Mol. Cell. Biol., June 15, 2004; 24(12): 5223 - 5234. [Abstract] [Full Text] [PDF]

				B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting Cancer Res., May 1, 2004; 64(9): 3350 - 3356. [Abstract] [Full Text] [PDF]

				G. Powis and L. Kirkpatrick Hypoxia inducible factor-1{alpha} as a cancer drug target Mol. Cancer Ther., May 1, 2004; 3(5): 647 - 654. [Abstract] [Full Text] [PDF]

				D. Hedley, M. Pintilie, J. Woo, T. Nicklee, A. Morrison, D. Birle, A. Fyles, M. Milosevic, and R. Hill Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis Am. J. Pathol., February 1, 2004; 164(2): 557 - 565. [Abstract] [Full Text] [PDF]

				R. N. Re Intracellular Renin and the Nature of Intracrine Enzymes Hypertension, August 1, 2003; 42(2): 117 - 122. [Abstract] [Full Text] [PDF]

				S. J. Welsh, R. R. Williams, A. Birmingham, D. J. Newman, D. L. Kirkpatrick, and G. Powis The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1{alpha} and Vascular Endothelial Growth Factor Formation Mol. Cancer Ther., March 1, 2003; 2(3): 235 - 243. [Abstract] [Full Text] [PDF]